CrkL meditates CCL20/CCR6-induced EMT in gastric cancer

Cytokine

Volumn 76, Issue 2, 2015, Pages 163-169

  Han, Gang ^a   Wu, Dawei ^b   Yang, Yongan ^b   Li, Zhiyun ^a   Zhang, Jiapin ^b   Li, Chengjun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b Huimin County Hospital of Shandong Province   (China)

Author keywords

CCL20 CCR6; CrkL; EMT; Erk1 2; Gastric cancer

Indexed keywords

CHEMOKINE RECEPTOR CCR6; CRK LIKE PROTEIN; GELATINASE A; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; PROTEIN KINASE B; VIMENTIN; CADHERIN; CCL20 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; DEFICIENCY; FOLLOW UP; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CADHERINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMOKINE CCL20; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FOLLOW-UP STUDIES; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; NUCLEAR PROTEINS; ONCOGENE PROTEIN V-AKT; PROGNOSIS; RECEPTORS, CCR6; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; VIMENTIN;

EID: 84943659979     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.05.009     Document Type: Article

References (30)

1. Assaraf Y.G., Leamon C.P., Reddy J.A. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Update 2014, 17(4-6):89-95.
2. Lianos G.D., Rausei S., Ruspi L., Galli F., Mangano A., Roukos D.H., et al. Laparoscopic gastrectomy for gastric cancer: current evidences. Int J Surg 2014, 12(12):1369-1373.
3. Deng J.Y., Liang H. Clinical significance of lymph node metastasis in gastric cancer. World J Gastroenterol 2014, 20(14):3967-3975.
4. Velho S., Fernandes M.S., Leite M., Figueiredo C., Seruca R. Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol 2014, 20(44):16433-16442.
5. Liu J., Zhang N., Li Q., Zhang W., Ke F., Leng Q., et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS ONE 2011, 6(4):e19495.
6. Ghadjar P., Coupland S.E., Na I.K., Noutsias M., Letsch A., Stroux A., et al. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 2006, 24(12):1910-1916.
7. Rubie C., Oliveira V., Kempf K., Wagner M., Tilton B., Rau B., et al. Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol 2006, 27(3):166-174.
8. Arai A., Aoki M., Weihua Y., Jin A., Miura O. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells. Cell Signal 2006, 18(12):2162-2171.
9. Wang Y., Dong Q.Z., Fu L., Stoecker M., Wang E., Wang E.H. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog 2013, 52(11):890-899.
10. Arai A., Kanda E., Nosaka Y., Miyasaka N., Miura O. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. J Biol Chem 2001, 276(35):33282-33290.
11. Guo C., Liu S., Sun M.Z. The role of CT10 regulation of kinase-like in cancer. Future Oncol 2014, 10(16):2687-2697.
12. Yang X., Li D., Cheng S., Fan K., Sheng L., Zhang J., et al. The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients. Tumour Biol 2014, 35(11):11091-11095.
13. Schutyser E., Struyf S., Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003, 14(5):409-426.
14. Huang F., Geng X.P. Chemokines and hepatocellular carcinoma. World J Gastroenterol 2010, 16(15):1832-1836.
15. Li L., Guris D.L., Okura M., Imamoto A. Translocation of CrkL to focal adhesions mediates integrin-induced migration downstream of Src family kinases. Mol Cell Biol 2003, 23(8):2883-2892.
16. Lamorte L., Royal I., Naujokas M., Park M. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Mol Biol Cell 2002, 13(5):1449-1461.
17. Zeng W., Chang H., Ma M., Li Y. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol 2014, 97(1):184-190.
18. Du D., Liu Y., Qian H., Zhang B., Tang X., Zhang T., et al. The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma. Int J Mol Sci 2014, 15(4):6441-6452.
19. Hou K.Z., Fu Z.Q., Gong H. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World J Gastroenterol 2015, 21(2):475-483.
20. Shi Y., Wu H., Zhang M., Ding L., Meng F., Fan X. Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma. Diagn Pathol 2013, 8:89.
21. Shih J.Y., Yang P.C. The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011, 32(9):1299-1304.
22. Chen X., Ye S., Xiao W., Wang W., Luo L., Liu Y. ERK1/2 pathway mediates epithelial-mesenchymal transition by cross-interacting with TGFβ/Smad and Jagged/Notch signaling pathways in lens epithelial cells. Int J Mol Med 2014, 33(6):1664-1670.
23. Zucchini-Pascal N., Peyre L., Rahmani R. Crosstalk between beta-catenin and snail in the induction of epithelial to mesenchymal transition in hepatocarcinoma: role of the ERK1/2 pathway. Int J Mol Sci 2013, 14(10):20768-20792.
24. Neuzillet C., Tijeras-Raballand A., de Mestier L., Cros J., Faivre S., Raymond E. MEK in cancer and cancer therapy. Pharmacol Ther 2014, 141(2):160-171.
25. Chowdhury I., Thompson W.E., Thomas K. Prohibitins role in cellular survival through Ras-Raf-MEK-ERK pathway. J Cell Physiol 2014, 229(8):998-1004.
26. Buonato J.M., Lazzara M.J. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res 2014, 74(1):309-319.
27. Yang P., Wang G., Huo H., Li Q., Zhao Y., Liu Y. SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial-mesenchymal transition via ERK and PI3K/AKT pathway. Med Oncol 2015, 32(1):377.
28. Zhou S.L., Zhou Z.J., Hu Z.Q., Li X., Huang X.W., Wang Z., et al. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett 2014, [pii: S0304-3835(14)00715-0].
29. Bhat F.A., Sharmila G., Balakrishnan S., Arunkumar R., Elumalai P., Suganya S., et al. Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. J Nutr Biochem 2014, 25(11):1132-1139.
30. Zhao T., Miao Z., Wang Z., Xu Y., Wu J., Liu X., et al. Overexpression of CRKL correlates with malignant cell proliferation in breast cancer. Tumour Biol 2013, 34(5):2891-2897.